Global Oncology Trends 2017 Ims Health

Thank you definitely much for downloading **global oncology trends 2017 ims health** .Maybe you have knowledge that, people have see numerous time for their favorite books bearing in mind this global oncology trends 2017 ims health , but stop happening in harmful downloads.

Rather than enjoying a good ebook as soon as a cup of coffee in the afternoon, otherwise they juggled once some harmful virus inside their computer. **global oncology trends 2017 ims health** is clear in our digital library an online permission to it is set as public hence you can download it instantly. Our digital library saves in fused countries, allowing you to get the most less latency time to download any of our books similar to this one. Merely said, the global oncology trends 2017 ims health is universally compatible bearing in mind any devices to read.

Encyclopedia of Public Health: Principles, People, and Programs [2 volumes] - Sally Kuykendall 2018-06-08
Providing context to today's public health practices and broad coverage of topics, this book demonstrates how cross-disciplinary studies are critical to addressing current health issues. • Presents complex health issues in ways that encourage readers to pursue the many different opportunities in the field of public health • Supplies insights from contributors that include experts on diseases such as hepatitis, substance abuse prevention, the history of medicine, and neurology • Provides a functional foundation for those working to improve the health of communities or individuals • Identifies relevant connections between physical, social, and emotional health and well-being to everyday life • Serves as a gateway to additional research and study by providing suggested further readings with each entry

New Health Technologies Managing Access, Value and Sustainability - OECD 2017-01-16
This report discusses the need for an integrated and cyclical approach to managing health technology in order to mitigate clinical and financial risks, and ensure acceptable value for money.

Current Challenges in Pharmacovigilance - World Health Organization 2001-01-01
In spite of recent progress in the harmonization of terminology and processes affecting work on the clinical safety of medicines consensus is needed on standards for many difficult aspects of day-to-day pharmacovigilance that continue to pose problems for both the pharmaceutical industry and drug regulators. The CIOMS V Working Group has generated proposals for pragmatic approaches to dealing with such issues as: classification and handling of individual safety case reports from a variety of sources (spontaneous consumer reports solicited reports literature the Internet observational studies and secondary data bases disease and other registries regulatory ADR databases and licensor-licensee interactions); new approaches to case management and regulatory reporting practices (proper clinical evaluation of cases incidental vs other events patient and reporter identifiability seriousness criteria expectedness criteria case follow-up criteria and the role and structure of case narratives); improvements and efficiencies in the format content and reporting of periodic safety update reports (PSURs) (including results of an industry survey on PSUR workloads and practices; proposals for high case volume and long time-period reports simplification of certain PSURs summary bridging reports addendum reports license renewal reports for EU and Japan dealing with old products and other technical details); determination and use of population exposure (denominator) data (sources of data and a guide to analytical approaches for a variety of circumstances).The Group has also taken stock of the current state of expedited and periodic clinical safety reporting requirements around the world with summary data on regulations from more than 60 countries. Recommendations are made for enhancing the harmonization steps already taken as a result of previous CIOMS publications and the ICH process. In addition to dealing with unfinished and unresolved issues from previous CIOMS initiatives the report covers many emerging topics such as those involving new technologies. Its 20 Appendices provide a wealth of detailed explanations and reference information. It is the most comprehensive and recent treatment of difficult pharmacovigilance issues affecting the working practices and systems of drug safety and other pharmaceutical professionals.

GIS Automated Delineation of Hospital Service Areas - Fahui Wang 2021-10-14
Hospital service areas (HSAs) and hospital referral regions (HRRs) are considered more appropriate units than geopolitical units for analyzing the performance of health care markets and policy implementation. GIS Automated Delineation of Hospital Service Areas represents the state-of-the-art approach in delineating HSAs and HRRs by using GIS-automated processes. It provides the best practices for defining such areas scientifically, in a geographically accurate manner, and without a steep learning curve. This book is intended to mainly serve professionals in geography, urban and regional planning, public health, and related fields. It is also useful for scholars in the above fields who have research interests related to GIS and spatial analysis applications in health care. It can be used as a supplemental text for upper-level undergraduate and graduate students in courses related to GIS and public health. Features: Introduces innovative state-of-the-art methods for delineation of HSAs (Dartmouth method, Huff model, network community detection methods) Provides best practices and one-stop solution for related data processing tasks (e.g., distance and travel time estimation, identifying the best-fitting distance decay function) Automates the methods in ArcGIS Pro toolkits Includes free ready-to-download GIS tools and sample data available on authors' website Presents a methodology that is applicable to delineation of other service areas, catchment areas or functional regions for business analysis, planning, and public policy studies

Health System and Reform in Lebanon - Walid Ammar 2003

Methods and Biostatistics in Oncology - Raphael. L.C Araújo 2018-04-16
This book introduces and discusses the most important aspects of clinical research methods and biostatistics for oncologists, pursuing a tailor-made and practical approach. Evidence-based medicine (EBM) has been in vogue in the last few decades, particularly in rapidly advancing fields such as oncology. This approach has been used to support decision-making processes worldwide, sparking new clinical research and guidelines on clinical and surgical oncology. Clinical oncology research has many peculiarities, including specific study endpoints, a special focus on survival analyses, and a unique perspective on EBM. However, during medical studies and in general practice, these topics are barely taught. Moreover, even when EBM and clinical cancer research are discussed, they are presented in a theoretical fashion, mostly focused on formulas and numbers, rather than on clinical application for a proper literature appraisal. Addressing that gap, this book discusses more practical aspects of clinical research and biostatistics in oncology, instead of relying only on mathematical formulas and theoretical considerations. Methods and Biostatistics in Oncology will help readers develop the skills they need to understand the use of research on everyday oncology clinical practice for study design and interpretation, as well to demystify the use of EBM in oncology.

OECD Health Policy Studies Pharmaceutical Innovation and Access to Medicines - OECD 2018-11-29
This report reviews the important role of medicines in health sytems, describes recent trends in pharmaceutical expenditure and financing, and summarises the approaches used by OECD countries to determine coverage and pricing.

Ensuring Quality Cancer Care Through the Oncology Workforce - Institute of Medicine 2009-04-28
The American Society of Clinical Oncology (ASCO) predicts that by 2020, there will be an 81 percent increase in people living with or surviving cancer, but only a 14 percent increase in the number of practicing oncologists. As a result, there may be too few oncologists to meet the population's need for cancer care. To help address the challenges in overcoming this potential crisis of cancer care, the National Cancer Policy Forum of the Institute of Medicine (IOM) convened the workshop Ensuring Quality Cancer Care through the Oncology Workforce: Sustaining Care in the 21st Century in Washington, DC on October 20 and 21, 2008.

Precision Oncology and Cancer Biomarkers - Anne Bremer 2022-03-29
This open access book reflects on matters of social and ethical concern raised in the daily practices of those working in and around precision

oncology. Each chapter addresses the experiences, concerns and issues at stake for people who work in settings where precision oncology is practiced, enacted, imagined or discussed. It subsequently discusses and analyses bioethical dilemmas, scientific challenges and economic trade-offs, the need for new policies, further technological innovation, social work, as well as phenomenological research. This volume takes a broad actor-centred perspective as, whenever cancer is present, the range of actors with issues at stake appears almost unlimited. This perspective and approach opens up the possibility for further in-depth and diverse questions, posed by the actors themselves, such as: How are cancer researchers navigating biological uncertainties? How do clinicians and policy-makers address ethical dilemmas around prioritisation of care? What are the patients' experiences with, and hopes for, precision oncology? How do policy-makers and entrepreneurs envisage precision oncology? These questions are of great interest to a broad audience, including cancer researchers, oncologists, policy-makers, medical ethicists and philosophers, social scientists, patients and health economists.

China's Technology Innovators - Xiaoming Zhu 2017-06-21

This book is one of the first to explore how Chinese companies are feeling the impulse of emerging business trends and seizing opportunities brought by technology innovation. It consists case studies of 7 Chinese companies: 3DMed, Wechat from Tencent, Shanghai GM, CP Group, Alibaba, AutoNavi, and ICBC. Each Chinese company has its unique perspectives and different ways to make transformation and business model adjustments. The book helps fill the gap between the global interest in "Innovate in China" and the limited availability of cases on innovations in the country. It is a valuable reference resource for readers in China and beyond wishing to address challenges in the context of growing digital technologies and overwhelming business trends.

Drug Delivery - Anya M Hillery 2016-09-15

This book provides a comprehensive introduction to advanced drug delivery and targeting, covering their principles, current applications, and potential future developments. This edition has been updated to reflect significant trends and cutting-edge advances that have occurred since the first edition was published. All the original chapters have been retained, but the material therein has been updated. Eight new chapters have been added that deal with entirely new technologies and approaches.

Global Pharmaceutical Policy - Zaheer-Ud-Din Babar 2020-06-15

Medicines are vital in improving patient health outcomes and pharmaceutical policy is a fundamental component of any health system. However, the global pharmaceutical policy is ever-evolving and data and quality 'research-based information' in this field are scarce. This book fills this gap and provides up-to-date empirical information and evidence-based synthesis. It focuses on pertinent key issues in global pharmaceutical policy including medicines safety, generic medicines, pharmaceutical supply chain, medicines financing, access and affordability of medicines, rational use of medicines, pharmacy health services research and access to vaccines and biological products. Featuring policy case studies from varied countries such as Mexico, Russia, China, Kyrgyzstan, and Pakistan, this book comprises a valuable and comprehensive resource for students, funders, policymakers, academics, and researchers interested in this field.

Healthcare in Private and Public from the Early Modern Period-to 2000 - Paul Weindling 2014-12-17

A key volume on a central aspect of the history of medicine and its social relations, The History of Healthcare in Public and Private examines how the modernisation of healthcare resulted in a wide variety of changing social arrangements in both public and private spheres. This book considers a comprehensive range of topics ranging from children's health, mental disorders and the influence of pharmaceutical companies to the systems of twentieth century healthcare in Britain, Eastern Europe and South Africa. Covering a broad chronological, thematic and global scope, chapters discuss key themes such as how changing economies have influenced configurations of healthcare, how access has varied according to lifecycle, ethnicity and wealth, and how definitions of public and private have shifted over time. Containing illustrations and a general introduction that outlines the key themes discussed in the volume, The History of Healthcare in Public and Private is essential reading for any student interested in the history of medicine.

Prevention Effectiveness - Anne C. Haddix 2003

Introduces readers to the concepts of decision and economic analysis, provides guidance on methods that will maximise the comparability of studies, and gives access to frequently used reference information. The second edition updates and expands upon the standard methodology for condcuting prevention effectiveness analyses.

Personalized Medicine as Innovation - Katharina Kichko 2019-09-21

Katharina Kichko supports the first Personalized Medicine learnings as she provides an approach overview in general as well as reimbursement and regulatory policies in particular. In focus stays analysis of the current Personalized Medicine in the U.S. and Germany as well as its preconditions for a wider implementation in the medical practice. Results have shown that the U.S. – as early knower – have the most projects as well as personalized drugs and therapies, while Germany – as a follower – has a significant number of projects and personalized products and more to come in future.

The 340B Program Handbook - Andrew L. Wilson 2018-05-15

Untangle New Requirements and Strengthen Your 340B Drug Program The 340B Program Handbook: Integrating 340B into the Health-System Pharmacy Supply Chain The 340B Drug Program Handbook is the comprehensive guide for pharmacy leaders, hospital administrators, legal counsel, and pharmacy managers. Developed by Andrew L. Wilson, PharmD, FASHP, this practical, clear-cut reference provides the most up-to-date information needed to implement and keep a high-performing program running well, including: · Complying with 340B requirements · Maintaining technical supply chain efficiency · Meeting effectiveness goals · Achieving heath-system financial objectives

Cancer Immunotherapy - George C. Prendergast 2011-04-28

There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease. * Offers a synthesis of concepts that are useful to cancer immunologists and pharmacologists, who tend to work in disparate fields with little cross-communication * Drs Prendergast and Jaffee are internationally recognized leaders in cancer biology and immunology who have created a unique synthesis of fundamental and applied concepts in this important new area of cancer research * Summarizes the latest insights into how immune escape defines an essential trait of cancer * Includes numerous illustrations including: how molecular-targeted therapeutic drugs or traditional chemotherapy can be combined with immunotherapy to improve anti-tumor efficacy; and how reversing immune suppression by the tumor can cause tumor regression

Medicamentos: ¿Derecho humano o negocio? - Lamata Cotanda, Fernando 2017-01-01

¬ Es la salud un derecho humano fundamental? ¬ Se está respetando ese derecho?¬ Hay personas que no pueden acceder a los medicamentos que necesitan? ¬ Cuántocuesta fabricar un medicamento? ¬ Por qué son los precios excesivos? ¬ Cuánto cuesta realmente la investigación? ¬ Por qué se conceden monopolios a las empresas a través de las patentes y la exclusividad de datos? ¬ Es verdad que se gastamás en marketing y en beneficios que en investigación? ¬ Tienen la misma causalos problemas de exceso y de acceso en relación con los medicamentos? ¬ Se haconvertido el medicamento en un producto financiero? El actual modelo es eficiente para las empresas pero, ¬ es eficiente para la sociedad? ¬ Hay alternativas?.Si la salud es un derecho humano fundamental, indispensable para el ejerciciode los demás derechos humanos, el acceso a los medicamentos es parte de ese derecho, y por lo tanto estamos obligados a contestar a estas incómodas preguntas, aunque solo sea porque una de cada tres personas en el mundo no tienen acceso a los medicamentos que necesitan, y en España, Portugal y otros países deUnión Europea, millones de personas no pudieron comprar en 2015 los medicamentos que les habían recetado sus médicos en la sanidad pública. El precio excesivo de los medicamentos (muy por encima del coste de fabricación y de I+D), además de suponer una barrera importante al acceso, provoca que la calidad de otras prestaciones se vea mermada y que se ponga en riesgo la estabilidad del sistema sanitario público. En la raíz del problema está un modelo que

prima más la visión del medicamento como producto financiero que como derecho de las personas. El equilibrio está roto. Además, este mismo modelo genera también el consumo innecesario de medicamentos y contribuye a un número muy elevado de reacciones adversas que causan muertes e importantes gastos. Estas y otras cuestiones se analizan con rigor en Medicamentos: ┐derecho humano o negocio?, donde los autores contestan a algunas de estas preguntas y animan a abrir un debate que ayude a promover la estabilidad de los sistemas sanitarios públicos y el acceso de todas las personas a los medicamentos necesarios.

Equity and Healthcare Reform in Developing Economies - Songül Çınaroğlu 2020-10-30

Ensuring equity in healthcare is the main concern of health policymakers in order to provide a sustainable health system. This concern is more prominent in developing countries due to the scarcity of resources. This book provides a comprehensive analysis and discussion on the distributive pattern of out-of-pocket pharmaceutical expenditures under the health reforms in Turkey and makes comparisons with pharmerging countries. Turkey's health reforms began in 2003 to address shortcomings related to financial protection and to improve health outcomes and the quality of healthcare services. The primary motivation was to ensure equity in the distribution of health resources, and this transformation process led to profound changes in how these resources were used, and in health financing in general. However, there is a lack of knowledge regarding the long-term effect of health reforms on the distribution patterns of health expenditures and health service use. This book offers a thorough equity analysis of the health financing system, affected by this health transformation program. Index and curve approaches are used in the equity analysis of pharmaceutical expenditures. The book examines the long-term effects of health system regulations on the health spending characteristics of households and improves the current understanding of equity in this context. It includes extensive international comparisons of healthcare services across a range of developing countries and highlights the significance of ensuring equity for emerging economies. The author explores the existing evidence as well as future research directions and provides policy and planning advice for health policymakers to contribute to establishing a more equal health system design. Additionally, the book will be of interest to scholars and professionals in the fields of health economics, public health management and health financing.

Empire of Pain - Patrick Radden Keefe 2021-04-13

NATIONAL BOOK CRITICS CIRCLE NOMINEE • A NEW YORK TIMES NOTABLE BOOK OF THE YEAR • NEW YORK TIMES BEST SELLER • A grand, devastating portrait of three generations of the Sackler family, famed for their philanthropy, whose fortune was built by Valium and whose reputation was destroyed by OxyContin. From the prize-winning and bestselling author of Say Nothing The history of the Sackler dynasty is rife with drama—baroque personal lives; bitter disputes over estates; fistfights in boardrooms; glittering art collections; Machiavellian courtroom maneuvers; and the calculated use of money to burnish reputations and crush the less powerful. The Sackler name has adorned the walls of many storied institutions—Harvard, the Metropolitan Museum of Art, Oxford, the Louvre. They are one of the richest families in the world, known for their lavish donations to the arts and the sciences. The source of the family fortune was vague, however, until it emerged that the Sacklers were responsible for making and marketing a blockbuster painkiller that was the catalyst for the opioid crisis. Empire of Pain begins with the story of three doctor brothers, Raymond, Mortimer and the incalculably energetic Arthur, who weathered the poverty of the Great Depression and appalling anti-Semitism. Working at a barbaric mental institution, Arthur saw a better way and conducted groundbreaking research into drug treatments. He also had a genius for marketing, especially for pharmaceuticals, and bought a small ad firm. Arthur devised the marketing for Valium, and built the first great Sackler fortune. He purchased a drug manufacturer, Purdue Frederick, which would be run by Raymond and Mortimer. The brothers began collecting art, and wives, and grand residences in exotic locales. Their children and grandchildren grew up in luxury. Forty years later, Raymond's son Richard ran the family-owned Purdue. The template Arthur Sackler created to sell Valium—co-opting doctors, influencing the FDA, downplaying the drug's addictiveness—was employed to launch a far more potent product: OxyContin. The drug went on to generate some thirty-five billion dollars in revenue, and to launch a public health crisis in which hundreds of thousands would die. This is the saga of three generations of a single family and the mark they would leave on the world, a tale that moves from the bustling streets of early twentieth-century Brooklyn to the seaside palaces of Greenwich, Connecticut, and Cap d'Antibes to the corridors of power in Washington, D.C. Empire of Pain chronicles the multiple investigations of the Sacklers and their company, and the scorched-earth legal tactics that the family has used to evade accountability. Empire of Pain is a masterpiece of narrative reporting and writing, exhaustively documented and ferociously compelling. It is a portrait of the excesses of America's second Gilded Age, a study of impunity among the super elite and a relentless investigation of the naked greed and indifference to human suffering that built one of the world's great fortunes.

Prescription Drug Diversion and Pain - John Peppin 2018-07-03

Prescription Drug Diversion and Pain provides an interdisciplinary overview of medications used to treat chronic pain, specifically the benefits and risks that are posed by long-term opioids use. These essential pain-relieving medications must be carefully managed to prevent serious side effects that may include physical dependence, addiction, and even death, which has led in recent years to increased attention on the development of alternative treatments for chronic pain. This book not only offers a single, comprehensive source for understanding the specialized field of the opioid crisis, but also addresses provocative topics including how pain drugs came to be regulated by the U.S. Government and the rarely-discussed aggressive marketing behind the spread of these drugs. Chapters are written by expert contributors from diverse backgrounds in medicine, psychiatry, pharmacy, nursing, health law, and ethics. Prescription Drug Diversion and Pain is a must-read for healthcare professionals, caregivers, policy makers, regulatory officials, law enforcement, and those in the pharmaceutical industry seeking to address the current and future opioid crisis.

Delivering Affordable Cancer Care in the 21st Century - Institute of Medicine 2013-06-20

Rising health care costs are a central fiscal challenge confronting the United States. National spending on health care currently accounts for 18 percent of gross domestic product (GDP), but is anticipated to increase to 25 percent of GDP by 2037. The Bipartisan Policy Center argues that "this rapid growth in health expenditures creates an unsustainable burden on America's economy, with far-reaching consequences". These consequences include crowding out many national priorities, including investments in education, infrastructure, and research; stagnation of employee wages; and decreased international competitiveness.In spite of health care costs that far exceed those of other countries, health outcomes in the United States are not considerably better. With the goal of ensuring that patients have access to high-quality, affordable cancer care, the Institute of Medicine's (IOM's) National Cancer Policy Forum convened a public workshop, Delivering Affordable Cancer Care in the 21st Century, October 8-9, 2012, in Washington, DC. Delivering Affordable Cancer Care in the 21st Century summarizes the workshop.

Cancer Control Opportunities in Low- and Middle-Income Countries - Institute of Medicine 2007-02-26

Cancer is low or absent on the health agendas of low- and middle-income countries (LMCs) despite the fact that more people die from cancer in these countries than from AIDS and malaria combined. International health organizations, bilateral aid agencies, and major foundations—which are instrumental in setting health priorities—also have largely ignored cancer in these countries. This book identifies feasible, affordable steps for LMCs and their international partners to begin to reduce the cancer burden for current and future generations. Stemming the growth of cigarette smoking tops the list to prevent cancer and all the other major chronic diseases. Other priorities include infant vaccination against the hepatitis B virus to prevent liver cancers and vaccination to prevent cervical cancer. Developing and increasing capacity for cancer screening and treatment of highly curable cancers (including most childhood malignancies) can be accomplished using "resource-level appropriateness" as a guide. And there are ways to make inexpensive oral morphine available to ease the pain of the many who will still die from cancer.

Integrating Clinical Research into Epidemic Response - National Academies of Sciences, Engineering, and Medicine 2017-07-26

The 2014â€"2015 Ebola epidemic in western Africa was the longest and most deadly Ebola epidemic in history, resulting in 28,616 cases and 11,310 deaths in Guinea, Liberia, and Sierra Leone. The Ebola virus has been known since 1976, when two separate outbreaks were identified in the Democratic Republic of Congo (then Zaire) and South Sudan (then Sudan). However, because all Ebola outbreaks prior to that in West

Africa in 2014â€"2015 were relatively isolated and of short duration, little was known about how to best manage patients to improve survival, and there were no approved therapeutics or vaccines. When the World Heath Organization declared the 2014-2015 epidemic a public health emergency of international concern in August 2014, several teams began conducting formal clinical trials in the Ebola affected countries during the outbreak. Integrating Clinical Research into Epidemic Response: The Ebola Experience assesses the value of the clinical trials held during the 2014â€"2015 epidemic and makes recommendations about how the conduct of trials could be improved in the context of a future international emerging or re-emerging infectious disease events.

The Price of Global Health - Ed Schoonveld 2020-05-17

The Price of Global Health is a unique book that describes the pharmaceutical pricing process and its business, economic and social challenges. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries, whose products are associated with death? The pharmaceutical industry is under unprecedented pressure due to a combination of declining R&D productivity, payer/provider demands for better value and public pressures to show pricing restraint. Rapidly increasing cost of healthcare, shifts from fee-for-service to value-based reimbursement, public pressure on drug pricing and an increasingly vocal medical community have empowered public and private payers worldwide to be more demanding on evidence of value for the prescription drugs that are brought to market. Pharmaceutical companies have often failed to deliver evidence of patient value, as development decision-making is overly focused on speed to FDA approval rather than speed to commercial success by effectively addressing the many “Access Journey” obstacles that typify today’s much changed pharmaceutical environment. This 3rd edition is significantly expanded with ten new chapters and revised and updated throughout to reflect today’s environment. The contents are reorganized to directly address critical pricing and patient access issues. Ed Schoonveld explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. His insights will help a wide range of audiences from healthcare industry professionals to policy makers, consumers, pharmaceutical company leaders and access and pricing professionals to gain a better understanding of this highly complex and emotionally charged field.

The Metabolic Approach to Cancer - Nasha Winters 2017

The Optimal Terrain Ten Protocol to Reboot Cellular Health Since the beginning of the twentieth century, cancer rates have increased exponentially--now affecting almost 50 percent of the American population. Conventional treatment continues to rely on chemotherapy, surgery, and radiation to attack cancer cells. Yet research has repeatedly shown that 95 percent of cancer cases are directly linked to diet and lifestyle. The Metabolic Approach to Cancer is the book we have been waiting for--it offers an innovative, metabolic-focused nutrition protocol that actually works. Naturopathic, integrative oncologist and cancer survivor Dr. Nasha Winters and nutrition therapist Jess Higgins Kelley have identified the ten key elements of a person's "terrain" (think of it as a topographical map of our body) that are crucial to preventing and managing cancer. Each of the terrain ten elements--including epigenetics, the microbiome, the immune system, toxin exposures, and blood sugar balance--is illuminated as it relates to the cancer process, then given a heavily researched and tested, non-toxic and metabolic, focused nutrition prescription. The metabolic theory of cancer--that cancer is fueled by high carbohydrate diets, not "bad" genetics--was introduced by Nobel Prize-laureate and scientist Otto Warburg in 1931. It has been largely disregarded by conventional oncology ever since. But this theory is resurging as a result of research showing incredible clinical outcomes when cancer cells are deprived of their primary fuel source (glucose). The ketogenic diet--which relies on the body's production of ketones as fuel--is the centerpiece of The Metabolic Approach to Cancer. Further, Winters and Kelley explain how to harness the anticancer potential of phytonutrients abundant in low-glycemic plant and animal foods to address the 10 hallmarks of cancer--an approach Western medicine does with drug based therapies. Their optimized, genetically-tuned diet shuns grains, legumes, sugar, genetically modified foods, pesticides, and synthetic ingredients while emphasizing whole, wild, local, organic, fermented, heirloom, and low-glycemic foods and herbs. Other components of their approach include harm-reductive herbal therapies like mistletoe (considered the original immunotherapy and common in European cancer care centers) and cannabinoids (which shrink tumors and increase quality of life, yet are illegal in more than half of the United States). Through addressing the ten root causes of cancer and approaching the disease from a nutrition-focused standpoint, we can slow cancer's endemic spread and live optimized lives.

Cardiovascular Complications in Cancer Therapy - Antonio Russo 2018-10-04

This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments the survival of cancer patients is enormously increasing, but at the same time it is increasing the burden of related cardiovascular complications that affect morbidity and mortality. On this basis a new branch of cardiology has been developed, that is Cardio-Oncology. The aim is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. An increasing attention has been given to cardiac damage, while, until today, vascular complications have been poorly evaluated. The aim of this book is to focus on vascular complications related to cancer treatment, to guide the clinician at facing, during his every day practice, cardiovascular toxicity in cancer and hematologic patients. The proposed sections of the book have been structured to review the molecular mechanisms underlying vascular damage induced by new and old treatments, to describe the various manifestations of vascular disease that may range from artery to venous disease (including coronary artery disease, peripheral arterial disease, venous thromboembolism and pulmonary hypertension), and to provide advice to monitor patients undergoing onco-hematologic treatments in order to prevent and eventually manage vascular damage.This book will address resident and fellow physicians, medical oncologists, cardiologists, general practitioners and all those who take care of these patients.All invited authors will be recognized experts in their field, and leading international researchers on these topics. The editor has worked with these expert colleagues on a variety of other projects. The authors will provide their manuscript according to current literature and clinical research studies. The book does not seek to duplicate or replace other current resources. Rather, it will create a comprehensive yet concise resource on this emerging topic that is not adequately covered by any current literature.

Brunner & Suddarth's Textbook of Medical-Surgical Nursing - Jan Hinkle 2017-09-25

Publisher’s Note: Products purchased from 3rd Party sellers are not guaranteed by the Publisher for quality, authenticity, or access to any online entitlements included with the product. Trusted by instructors, preferred by students, Brunner & Suddarth’s Textbook of Medical-Surgical Nursing, 14th Edition makes fundamental coverage of medical-surgical nursing practices more approachable than ever. Comprehensively updated to keep pace with today’s changing health care environment, this edition layers essential patient care procedures with engaging case studies and vignettes that bring concepts to life and prepare students to confidently apply what they’ve learned in nursing practice. Fully updated and enhanced, this new edition provides a fully integrated solution that promotes clinical judgment, performance, and success on the NCLEX examination and in nursing practice.

Arzneiverordnungs-Report 2017 - Ulrich Schwabe 2017-10-24

Im seit 1985 jährlich als Buch erscheinenden Arzneiverordnungs-Report werden die Rezepte für die Patienten der gesetzlichen Krankenversicherung (GKV) mit Methoden der evidenzbasierten Medizin analysiert.Seit dieser Zeit bietet der Report eine unabhängige Informationsmöglichkeit über die verschiedenen Komponenten der Arzneimittelverordnung und trägt damit zur Transparenz des Arzneimittelmarkts, zur Bewertung von Arzneimitteln und zu einer sowohl zweckmäßigen und sicheren evidenzbasierten als auch wirtschaftlichen Arzneitherapie bei.

Delivering Quality Health Services: A Global Imperative - OECD 2018-07-05

This report describes the current situation with regard to universal health coverage and global quality of care, and outlines the steps governments, health services and their workers, together with citizens and patients need to urgently take.

Indonesia 2045 - Mata Garuda 2018-08-24

“Aku pasti mengabdi!” Kalimat itulah yang selalu bergema dalam diri para penerima beasiswa LPDP. Kesempatan besar yang telah diberikan

oleh pemerintah Indonesia tentu tak boleh disia-siakan. Dan, kontribusi pemikiran menjadi salah satu jalan pengabdian. Saat ini, Indonesia tengah berlari menuju posisi penting di kancah internasional. Misi besar itu akan diwujudkan dalam “Indonesia Emas 2045”. Melalui misi tersebut, dalam buku ini, para peraih beasiswa LPDP menuangkan gagasan besarnya dalam berbagai bidang. Melalui esai-esai kritis dan penuh inovasi segar inilah, mereka berusaha membangun Indonesia sebagai negara membanggakan bagi generasi anak cucu kita kelak. [Mizan, Bentang Pustaka, Motivasi, Inspirasi, Kisah Inspiratif, Semangat, Perjuangan, Negara, Indonesia]

Prescription for the People - Fran Quigley 2017-11-15

In Prescription for the People, Fran Quigley diagnoses our inability to get medicines to the people who need them and then prescribes the cure. He delivers a clear and convincing argument for a complete shift in the global and U.S. approach to developing and providing essential medicines—and a primer on how to make that change happen. Globally, 10 million people die each year because they are unable to pay for medicines that would save them. The cost of prescription drugs is bankrupting families and putting a strain on state and federal budgets. Patients’ desperate need for affordable medicines clashes with the core business model of the powerful pharmaceutical industry, which maximizes profits whenever possible. It doesn’t have to be this way. Patients and activists are aiming to make all essential medicines affordable by reclaiming medicines as a public good and a human right, instead of a profit-making commodity. In this book, Quigley demystifies statistics and terminology, offers solutions to the problems that block universal access to medicines, and provides a road map for activists wanting to make those solutions a reality.

WHO guideline on country pharmaceutical pricing policies - 2020-09-29

In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems' ability to provide population-wide access to essential medicines. Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products. This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.

Hepatitis B Virus in Human Diseases - Yun-Fan Liaw 2015-11-13

This text provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for students, clinicians, and researchers with an interest in hepatitis B. The book reviews new data about basic and translational science including the viral life cycle, the immunopathogenesis of virus induced chronic hepatitis, the mechanism of virus induced liver cancer, and their potential applications for the clinical management of patients. The clinical aspects of this chronic viral infection are reviewed in detail with important chapters on the global epidemiology, the natural history of the disease, co-infections with its satellite virus HDV or HIV, and management of special patient populations. A major emphasis is made on the management of antiviral therapy and the recent international guidelines for the treatment of hepatitis B. Finally, the book reviews the current state of the art regarding immunoprophylaxis to prevent the spread of the virus and its major clinical consequences. The new advances and perspectives in the development of improved antiviral treatments are also discussed. Hepatitis B Virus in Human Diseases will serve as a very useful resource for students, physicians and researchers dealing with, and interested in, this challenging chronic viral infection. It will provide a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and include the most up to date scientific and clinical information.

Pain Management and the Opioid Epidemic - National Academies of Sciences, Engineering, and Medicine 2017-09-28

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

Oncologic Emergency Medicine - Knox H. Todd 2021-04-22

The expanded second edition of this key clinical reference provides the most up-to-date and comprehensive review of oncologic emergencies. It covers the diagnosis and management of the full range of emergencies caused directly by cancer and/or treatment, including chemotoxicity, radiotoxicity and post-surgical complications, as well as transplant-related issues and toxicities of novel antineoplastic agents and the new immunotherapies. The book also shows how the entire spectrum of clinical medicine is brought to bear in the care of cancer patients in the unique setting of the emergency department (ED), from health promotion and prevention, to treatment and palliative care. Recognizing the multiple, overlapping contexts in which emergency care of cancer patients occurs, the book addresses clinically crucial interdisciplinary topics such as the ethics of ED cancer care, analgesic misuse and abuse, informatics, quality improvement and more. Finally, perspectives on care system and social forces that shape ED cancer care, such as cancer care disparities and care models, frame the book as a whole. Edited and written by world-renowned experts in emergency medicine and oncology, the Second Edition of Oncologic Emergency Medicine: Principles and Practice is the definitive resource for emergency physicians, oncologists, internists, family physicians, emergency nurses, nurse practitioners, physician assistants, and policy makers as well as pre and postgraduate trainees.

Regulatory and Economic Aspects in Oncology - Evelyn Walter 2018-12-13

This book explores topics of importance to all who have an interest in economic methods for assessment of the efficacy and effectiveness of new cancer treatments and in regulatory measures relating to their marketing authorization and pricing. Targeted therapies and modern immunotherapy are placing a substantial strain on health care budgets. Regulation and economic methods to assess the parameters for establishing efficacy and effectiveness are therefore of prime importance. Payer authorities have to determine whether the use of these novel therapies yields clinical benefits that justify their increasing cost. In the simplest terms, cost-effectiveness analyses quantify the ratio between the extent to which an intervention raises healthcare costs and the extent to which it improves health outcomes. Rigorous cost-effectiveness analyses translate all health outcomes into quality-adjusted life years. On the other hand, in order to sustain innovation, price regulations must be coupled with efforts to ensure that drug companies are still able to recoup their investments in high-risk and high-costs research programs. Ultimately, decisions regarding health care expenditures are also a question of society’s willingness to pay.

Ensuring Quality Cancer Care - Institute of Medicine and National Research Council 1999-07-21

We all want to believe that when people get cancer, they will receive medical care of the highest quality. Even as new scientific breakthroughs are announced, though, many cancer patients may be getting the wrong care, too little care, or too much care, in the form of unnecessary procedures. How close is American medicine to the ideal of quality cancer care for every person with cancer? Ensuring Quality Cancer Care provides a comprehensive picture of how cancer care is delivered in our nation, from early detection to end-of-life issues. The National Cancer Policy Board defines quality care and recommends how to monitor, measure, and extend quality care to all people with cancer. Approaches to accountability in health care are reviewed. What keeps people from getting care? The book explains how lack of medical coverage, social and economic status, patient beliefs, physician decision-making, and other factors can stand between the patient and the best possible care. The board explores how cancer care is shaped by the current focus on evidence-based medicine, the widespread adoption of managed care, where services are provided, and who provides care. Specific shortfalls in the care of breast and prostate cancer are identified. A status report on health services research is included. Ensuring Quality Cancer Care offers wide-ranging data and information in clear context. As the baby

boomers approach the years when most cancer occurs, this timely volume will be of special interest to health policy makers, public and private healthcare purchasers, medical professionals, patient advocates, researchers, and people with cancer.

Drug Repurposing - David Cavalla 2022-02-09

Drug repurposing is the development of existing drugs for new uses: given that 9 in 10 drugs that enter drug development are never marketed and therefore represent wasted effort, it is an attractive as well as inherently more efficient process. Three repurposed drugs can be brought to market for the same cost as one new chemical entity; and they can also be identified more quickly, an important benefit for patients whose diseases are progressing faster than therapeutic innovation. But repurposing also requires a fresh look at configuring pharmaceutical R&D, considering clinical, regulatory and patent issues much earlier than would otherwise be the case; a holistic gedanken experiment almost needs to be undertaken at the very start of any repurposing development. In addition to new ways of thinking, the discovery of repurposing opportunities can take advantage of artificial intelligence techniques to match the perfect new use for an existing drug. And while repurposing of medicines has been in the mind of every doctor since Hypocrates, modern clinical practice will simply have to adapt to new repurposing techniques in an age where the number of known diseases is increasing much faster than the healthcare dollars available.

Biogenic Nanoparticles for Cancer Theranostics - Chittaranjan Patra 2021-06-01

Biogenic Nanoparticles for Cancer Theranostics outlines the synthesis of biogenic nanoparticles to become cancer theranostic agents. The book also discusses their cellular interaction and uptake, pharmacokinetics, biodistribution, drug delivery efficiency, and other biological effects. Additionally, the book explores the mechanism of their penetration in cancerous tissue, its clearance, and its metabolism. Moreover, the in vitro and in vivo toxicological effects of biogenic nanoparticles are discussed. This book is an important reference source for materials scientists and biomedical scientists who are looking to increase their understanding of how biogenic nanoparticles are being used for a range of cancer treatment types. Metal nanoparticles have traditionally been synthesized by classical physico-chemical methods which have many drawbacks, such as high energy demand, high cost and potential ecotoxicity. As a result, the biosynthesis of metal nanoparticles is gaining increasing prominence. Biosynthesis approaches to metal nanoparticles are clean, safe, energy efficient and environment friendly. Explains the synthesis methods and applications of biogenic nanoparticles for cancer theranostics Outlines the distinctive features of biogenic nanoparticles that make them effective cancer treatment agents Assesses the major challenges of using biogenic nanoparticles on a mass scale